IFNB1 Protein (AA 22-187)

Catalog No. ABIN8056988

Recombinant IFNB1 protein expressed in HEK-293 Cells.

Quick Overview for IFNB1 Protein (AA 22-187) (ABIN8056988)

Target: IFNB1 (Interferon, beta 1, Fibroblast (IFNB1))

Protein Type: Recombinant

Origin: Human

Source: HEK-293 Cells

Application: Immunogen (Imm)

Purity: > 95 % as determined by reducing SDS-PAGE.

Product Details

Protein Characteristics: AA 22-187

Purpose: Recombinant Human IFN-β Protein(Halo Tag)

Sequence: Met22-Asn187

Sterility: 0.2 μm filtered

Endotoxin Level: < 1.0 EU/mg of the protein as determined by the LAL method

Biological Activity Comment: Not validated for activity

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis.

Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with 5 % Trehalose and 5 % Mannitol.

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Expiry Date: 12 months

Target Details

Target: IFNB1 (Interferon, beta 1, Fibroblast (IFNB1))

Alternative Name: IFN-beta

Background: Interferon beta,IFNB,Fibroblast interferon,Interferons (IFNs) are natural glycoproteins belonging to the cytokine superfamily and are produced by the cells of the immune system of most vertebrates in response to challenges by foreign agents such as viruses, parasites, and tumor cells. Interferon-beta (IFN beta) is an extracellular protein mediator of host defense and homeostasis. IFN beta has well-established direct antiviral, antiproliferative, and immunomodulatory properties. Recombinant IFN beta is approved for the treatment of relapsing-remitting multiple sclerosis. The recombinant IFN beta protein has the theoretical potential to either treat or causes autoimmune neuromuscular disorders by altering the complicated and delicate balances within the immune system networks. It is the most widely prescribed disease-modifying therapy for multiple sclerosis (MS). Large-scale clinical trials have established the clinical efficacy of IFN beta in reducing relapses and slowing disease progression in relapsing-remitting MS. IFN beta therapy was shown to be comparably beneficial for opticospinal MS (OSMS) and conventional MS in Japanese. IFN beta is effective in reducing relapses in secondary progressive MS and may have a modest effect in slowing disability progression. In addition to the common antiviral activity, IFN beta also induces increased production of the p53 gene product which promotes apoptosis and thus has a therapeutic effect against certain cancers. The role of IFN-beta in bone metabolism could warrant its systematic evaluation as a potential adjunct to therapeutic regimens of osteolytic diseases. Furthermore, IFN beta might play a beneficial role in the development of chronic progressive CNS inflammation.

Molecular Weight:

Calculated MW: 51.1 kDa

Observed MW: 55 kDa

Gene ID: 3456

UniProt: P01574

Pathways: JAK-STAT Signaling, TCR Signaling, TLR Signaling, Regulation of Leukocyte Mediated Immunity, Production of Molecular Mediator of Immune Response, Positive Regulation of Endopeptidase Activity, Hepatitis C, Autophagy, Inflammasome